Trials / Completed
CompletedNCT03126591
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaratumab | Administered IV |
| DRUG | Pembrolizumab (KEYTRUDA®) | Administered IV |
Timeline
- Start date
- 2017-07-03
- Primary completion
- 2021-05-06
- Completion
- 2023-02-21
- First posted
- 2017-04-24
- Last updated
- 2024-10-23
- Results posted
- 2024-10-23
Locations
6 sites across 4 countries: United States, Belgium, Denmark, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03126591. Inclusion in this directory is not an endorsement.